Towa Pharmaceutical Co., Ltd. signed an agreement to acquire Pensa Investments S.L. from Esteve Pharmaceuticals, S.A.
December 22, 2019
Share
Towa Pharmaceutical Co., Ltd. (TSE:4553) signed an agreement to acquire Pensa Investments S.L. from Esteve Pharmaceuticals, S.A. on December 23, 2019. The purchase price of Pensa will be an all cash deal with an upfront payment of €320 million. This acquisition is scheduled to be completed by the end of January 2020. Lazard Asesores Financieros, S.A. acted as financial advisor to Esteve Pharmaceuticals, S.A. Barclays Securities Japan Limited acted as financial advisor and Monica Weimann of Gómez-Acebo & Pombo Abogados, S.L.P. acted as legal advisor to Towa Pharmaceutical Co., Ltd. Guillermo Guardia, José María Vilaseca, Juan Cuerva, Cristina González, Manel Santilari, Francisco Ruiz, Begoña Barrantes, Thais Garcia, Daryl Fairbairn, Timothy Cornell, Natsuko Sugihara, Yuki Hoshinaga and Fernando Escribano of Clifford Chance S.L.P. acted as legal advisors for Esteve Pharmaceuticals.
Towa Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The main products are generic drugs, which are launched after the efficacy and safety of new drugs have been confirmed for a certain period of time. It is a drug with the same effect, usage and dosage. The Company is involved in the sale and outsourced manufacture of products and generic drugs. The Company is involved in the research and outsourced manufacture of active pharmaceutical ingredient and soft capsules. The Company is also involved in the planning, development, contract manufacturing of health foods, general foods, miscellaneous goods and others.
TOWA PHARMACEUTICAL CO., LTD. 
